Neural Analytics, a San Francisco, CA-based medical device company developing and commercializing technology to measure, diagnose and track brain health, raised $10m in financing.
The round was led by Reimagined Ventures. In conjunction with the funding, Ted Koutouzis, M.D. of Reimagined Ventures, will join Neural Analytics’ Board of Directors.
The company intends to use the funds to expand commercialization efforts for the Lucid System both in the U.S. and Europe and continue its ongoing research efforts.
Led by Leo Petrossian, Ph.D., Chief Executive Officer, Neural Analytics creates products and services to measure, diagnose and track brain health. They combine data science with hardware to allow first responders and clinicians to assess and monitor brain health issues.
The Lucid M1 Transcranial Doppler Ultrasound System, which has received both FDA clearance and CE Mark approval, is designed for measuring and displaying cerebral blood flow velocities and monitoring of patients with brain disorders.
The system is currently available in the U.S. and Europe.
The company is also conducting a feasibility study with the Erlanger Health System in Chattanooga, Tennessee to evaluate the Lucid System for patients suffering an acute ischemic stroke.